ODT’s Most-Read Stories This Week—July 20

New products and a partnership among ODT’s top 10 companies produced peak pageview performance this past week. 

Smith+Nephew outpaced its top 10 rivals with word of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System, a product designed to address the evolving demands of primary hip surgery—particularly the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs). The CATALYSTEM Primary Hip System was developed using global data sets across femoral morphologies to help deliver a precision fit. Featuring a triple-taper stem design with uniform proximal loading, the reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches. The CATALYSTEM Primary Hip System also uses proprietary, patent-pending, ACCUBROACH Technology to deliver proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.

Trailing Smith+Nephew in cybervisits was Stryker Corp., which closed its acquisition of Artelon, a privately held company that specializes in soft tissue fixation products for foot and ankle, and sports medicine procedures. Artelon’s synthetic technology is designed to boost biological and mechanical alignment and tendon reconstruction. Its tech has been used in more than 60,000 implantations worldwide, according to the company. The acquisition, first revealed last month, allows Stryker to have a more competitive position in the foot/ankle and sports medicine segment with a biomaterial technology that supports healing of soft tissues. 

Other new product news came from Paradigm Biodevices and Globus Medical. The former drove significant traffic by launching VisiCORE, a new bone graft harvesting system for foot and ankle fusion surgeries. VisiCORE features a clear collection tube with the company’s proprietary Graft Retention Technology (GRT). The system allows bone graft harvests to be seen in real-time. 

Globus Medical, meanwhile, gained favor with cybervisitors for earning FDA 510(k) clearance for its ExcelsiusFlex with total knee arthroplasty (TKA) application and Actify 3D total knee system to pair with it. ExcelsiusFlex assists surgeons in primary TKA for robotically-guided resections based on their implant placement planning. Its unrestricted jig-less resections and multiple workflows help restore control of the saw and procedure to the surgeon. When used with Globus’ ExcelsiusHub, ExcelsiusFlex is an aid to precisely locate anatomical structures and for tool holder spatial positioning and orientation. This way, surgeons can navigate and/or guide compatible instruments, provided the needed fiducial markets and rigid patient anatomy can be identified on CT scans, fluoroscopy, or directly acquired anatomical structures. The Actify 3D knee pairs cementless reconstruction with an anatomic fit. It’s additive engineered, combining strength and a porous lattice interface. 
 

1. FDA Clears Smith+Nephew’s CATALYSTEM Primary Hip System

2. Stryker Completes Deal for Soft Tissue Fixation Firm Artelon

3. Paradigm Biodevices Rolls Out VisiCORE MIS Bone Graft Harvester

4. Globus Wins FDA Nods for ExcelsiusFlex Robotic Navigation & Actify 3D Total Knee

5. Loci Orthopaedics Raises €12.8M in Series A